$-0.05 EPS Expected for IntelliPharmaCeutics International Inc. (IPCI)

March 15, 2018 - By Darrin Black

 $ 0.05 EPS Expected for IntelliPharmaCeutics International Inc. (IPCI)

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.05 EPS on April, 10.They anticipate $0.02 EPS change or 28.57 % from last quarter’s $-0.07 EPS. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -37.50 % EPS growth. The stock increased 15.77% or $0.088 during the last trading session, reaching $0.649. About 897,327 shares traded or 146.68% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since March 15, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. Maxim Group maintained the stock with “Buy” rating in Friday, June 30 report. As per Monday, March 5, the company rating was maintained by H.C. Wainwright. The rating was maintained by Maxim Group on Friday, July 21 with “Buy”. Maxim Group maintained IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) rating on Tuesday, June 6. Maxim Group has “Buy” rating and $600 target. The rating was maintained by H.C. Wainwright with “Buy” on Monday, February 12. The rating was maintained by Maxim Group on Thursday, December 31 with “Buy”. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has “Hold” rating given on Friday, February 16 by Maxim Group.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $22.51 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: Marketwatch.com which released: “Intellipharmaceutics International Inc.” on July 27, 2017, also Globenewswire.com with their article: “Intellipharmaceutics Provides Operational Update” published on January 24, 2018, Globenewswire.com published: “Intellipharmaceutics Reports on Launch of Additional Strengths of Generic …” on November 30, 2017. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: Streetinsider.com and their article: “Intellipharmaceutics (IPCI) Announces 5.83M Share Registered Direct Offering …” published on March 14, 2018 as well as Globenewswire.com‘s news article titled: “Intellipharmaceutics Announces Closing of US$4 Million Financing” with publication date: October 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.